Breadcrumb Home Business Activities Lundbeckfonden BioCapital ZIARCO Pharma ZIARCO Pharma Developed dermatological drugs, the lead being an H4 receptor antagonist tested in Atopic Dermatitis and Psoriasis patients. Related news about ZIARCO Pharma Novartis bolsters innovative dermatology portfolio through acquisition of Ziarco Group Limited Ziarco Pharma Ltd: Ziarco reports positive Phase 2a study results with ZPL-389 in moderate to severe atopic dermatitis patients Ziarco Pharma Announces Positive Top Line Results from Phase 2a Study in Moderate to Severe Atopic Dermatitis with its Oral Lead Compound ZPL-389 Ziarco Pharma Ltd: Appointment of Dr. Arvind Hundal as Chief Business Officer Phase 2a Psoriasis Study Initiated with Ziarco’s Lead Compound ZPL-389 Lundbeckfonden BioCapital Invested 2014 Acquired by Novartis in 2016 Location San Francisco, California, USA
